Omega Diagnostics Directors


Colin King, MBA Chief Executive Officer

Colin joined Omega in August 2015 as Chief Operating Officer. He has worked in the medical diagnostics industry for 23 years, previously working for Axis-Shield. He joined them in 1995 and held a number of positions encompassing planning, supply chain, project management and operations and, ultimately, from 2007
was Managing Director of the Laboratory division. During his time as Managing Director he was responsible for leading its diversification strategy, which was successful in maintaining revenues despite retiring two key product revenue lines. Colin was appointed Chief Executive Officer on 14 December 2017, with key responsibility for implementation of the recent strategic review.

Simon DouglasChairman

Simon was appointed Chairman in February 2021.  He has over 30 years’ experience in the biotech industry, including 10 years working for Amersham International (now GE), ICI and Zeneca (now Astra Zeneca), in a variety of commercial and technical positions, and over five years with Tepnel Life Sciences plc (now Hologic Inc), a London Stock Exchange listed diagnostic company where he was Chief Executive. He has been the CEO/Executive Chairman on three other venture capital backed Life Science companies, and headed up the trade sale of two of these. He is currently Chairman of both Fusion Antibodies plc, an AIM listed CRO providing services for the discovery and development of antibody based therapies and C-Major Medical, a venture capital backed Medical Device Company. 

Christopher Lea Group Finance Director

Chris joined Omega on 30 August 2021 as Chief Financial Officer and Company Secretary. He is responsible for finance, tax, auditing, company secretarial and supporting the CEO with investor relations. He was previously CFO of two other AIM-listed companies, IndigoVision Group plc and Superglass Holdings PLC, both of which were successfully turned around under Chris’ management and were subsequently acquired by larger corporations.  IndigoVision was one of the larger independent, end-to-end CCTV system manufacturers, operating worldwide from its Edinburgh HQ and was acquired by Motorola Solutions, Inc in June 2020.  Prior to its sale in 2016, Superglass was the UK’s only independent manufacturer of glass wool insulation and is now part of TechnoNICOL International, a leading producer of construction materials.
Prior to his public company roles, Chris was CFO of Aviagen Europe, the world’s largest poultry breeding company, where he helped grow Aviagen’s European business five-fold over a 10 year period, through a combination of organic growth and multiple strategic acquisitions.  Chris spent 15 years with KPMG, holding various roles in their audit and corporate finance business.  He holds a BSc (Hons) in Physics from Nottingham University and is a member of the Institute of Chartered Accountants in England and Wales. 

Jag Grewal, Group Sales & Marketing DirectorManaging Director, Health and Nutrition Division

Jag joined Omega in June 2011 as Group Sales and Marketing Director. He has worked in the medical diagnostics industry for 22 years having started out as a Clinical Biochemist in the NHS. In 1995 he joined Beckman Instruments where he developed a career spanning 15 years in sales and marketing holding a variety of positions in sales, product management and marketing management. In 2009 he left his position of Northern Europe Marketing Manager to join Serco Health, where he helped create
the first joint venture within UK pathology between Serco and Guy’s and St Thomas’ Hospital. He is also past Chairman and current Treasurer of the British In Vitro Diagnostics Association (BIVDA). Jag is currently responsible for managing the Health and Nutrition division as well as contributing to overall group commercial strategy and development.

William Rhodes, BS, MSIB Non-executive Director

During his 14-year career with Becton, Dickinson and Company, one of the world’s leading suppliers of medical, diagnostic and life science research products, Bill held a number of senior leadership positions and, until the end of 2012, was BD’s Senior Vice President, Corporate Strategy and Development, being responsible for BD’s worldwide mergers and acquisitions and corporate strategies. Previously, he was Worldwide President of BD Biosciences, a business segment with turnover of over US$1.0 billion, including the provision of flow cytometry instruments and their associated reagents for CD4 testing used in a wide range of laboratory settings. Prior to working for BD, Bill held senior business development positions with Pfizer Inc. and Johnson and Johnson.

Jeremy MillardNon-executive Director

Jeremy has 20 years’ investment banking experience and was previously a partner at Smith Square Partners LLP where he provided strategic and corporate advice to clients in the science, technology and telecommunications sectors, prior to which he headed up the technology practice at Rothschild in London. Jeremy is currently a Non-executive Director and chairman of the audit committee of AIM-listed Idox plc and a Non-executive Director of AIM-listed Ilika Plc.